scholarly journals Tolerability and Efficacy of s.c. IgG Self-Treatment in ME/CFS Patients with IgG/IgG Subclass Deficiency: A Proof-of-Concept Study

2021 ◽  
Vol 10 (11) ◽  
pp. 2420
Author(s):  
Carmen Scheibenbogen ◽  
Franziska Sotzny ◽  
Jelka Hartwig ◽  
Sandra Bauer ◽  
Helma Freitag ◽  
...  
Keyword(s):  
Primary Outcome ◽  
Complex Disease ◽  
Chronic Fatigue ◽  
Igg Subclass ◽  
Proof Of Concept ◽  
Igg Subclass Deficiency ◽  
Fatigue Syndrome ◽  
Potential Biomarker ◽  
Sf 36 ◽  
Subclass Deficiency

Background: Chronic fatigue syndrome (ME/CFS) is a complex disease frequently triggered by infections. IgG substitution may have therapeutic effect both by ameliorating susceptibility to infections and due to immunomodulatory effects. Methods: We conducted a proof of concept open trial with s.c. IgG in 17 ME/CFS patients suffering from recurrent infections and mild IgG or IgG subclass deficiency to assess tolerability and efficacy. Patients received s.c. IgG therapy of 0.8 g/kg/month for 12 months with an initial 2 months dose escalation phase of 0.2 g and 0.4 g/kg/month. Results: Primary outcome was improvement of fatigue assessed by Chalder Fatigue Scale (CFQ; decrease ≥ 6 points) and of physical functioning assessed by SF-36 (increase ≥ 25 points) at month 12. Of 12 patients receiving treatment per protocol 5 had a clinical response at month 12. Two additional patients had an improvement according to this definition at months 6 and 9. In four patients treatment was ceased due to adverse events and in one patient due to disease worsening. We identified LDH and soluble IL-2 receptor as potential biomarker for response. Conclusion: Our data indicate that self-administered s.c. IgG treatment is feasible and led to clinical improvement in a subset of ME/CFS patients.

IgG SUBCLASS DEFICIENCY AND CHRONIC FATIGUE SYNDROME

The Lancet ◽  
1988 ◽  
Vol 331 (8590) ◽  
pp. 885-886 ◽  
Author(s):  
Annika Linde ◽  
Lennart Hammrström ◽  
C.I. Edvard Smith
Keyword(s):  
Chronic Fatigue Syndrome ◽  
Chronic Fatigue ◽  
Igg Subclass ◽  
Igg Subclass Deficiency ◽  
Fatigue Syndrome ◽  
Subclass Deficiency

scholarly journals Systematic Review of Primary Outcome Measurements for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) in Randomized Controlled Trials

2020 ◽  
Vol 9 (11) ◽  
pp. 3463
Author(s):  
Do-Young Kim ◽  
Jin-Seok Lee ◽  
Chang-Gue Son
Keyword(s):  
Chronic Fatigue Syndrome ◽  
Randomized Controlled Trials ◽  
Primary Outcome ◽  
Chronic Fatigue ◽  
Myalgic Encephalomyelitis ◽  
Cochrane Library ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Fatigue Syndrome ◽  
Sf 36

Background: Due to its unknown etiology, the objective diagnosis and therapeutics of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) are still challenging. Generally, the patient-reported outcome (PRO) is the major strategy driving treatment response because the patient is the most important judge of whether changes are meaningful. Methods: In order to determine the overall characteristics of the main outcome measurement applied in clinical trials for CFS/ME, we systematically surveyed the literature using two electronic databases, PubMed and the Cochrane Library, throughout June 2020. We analyzed randomized controlled trials (RCTs) for CFS/ME focusing especially on main measurements. Results: Fifty-two RCTs out of a total 540 searched were selected according to eligibility criteria. Thirty-one RCTs (59.6%) used single primary outcome and others adapted ≥2 kinds of measurements. In total, 15 PRO-derived tools were adapted (50 RCTs; 96.2%) along with two behavioral measurements for adolescents (4 RCTs; 7.7%). The 36-item Short Form Health Survey (SF-36; 16 RCTs), Checklist Individual Strength (CIS; 14 RCTs), and Chalder Fatigue Questionnaire (CFQ; 11 RCTs) were most frequently used as the main outcomes. Since the first RCT in 1996, Clinical Global Impression (CGI) and SF-36 have been dominantly used each in the first and following decade (26.1% and 28.6%, respectively), while both CIS and Multidimensional Fatigue Inventory (MFI) have been the preferred instruments (21.4% each) in recent years (2016 to 2020). Conclusions: This review comprehensively provides the choice pattern of the assessment tools for interventions in RCTs for CFS/ME. Our data would be helpful practically in the design of clinical studies for CFS/ME-related therapeutic development.

scholarly journals Bioenergetic and Proteomic Profiling of Immune Cells in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients: An Exploratory Study

Biomolecules ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 961
Author(s):  
Paula Fernandez-Guerra ◽  
Ana C. Gonzalez-Ebsen ◽  
Susanne E. Boonen ◽  
Julie Courraud ◽  
Niels Gregersen ◽  
...  
Keyword(s):  
Chronic Fatigue Syndrome ◽  
Complex Disease ◽  
Mononuclear Cells ◽  
Coupling Efficiency ◽  
Well Being ◽  
Chronic Fatigue ◽  
Myalgic Encephalomyelitis ◽  
Flux Analysis ◽  
Proteomic Profiling ◽  
Fatigue Syndrome

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a heterogeneous, debilitating, and complex disease. Along with disabling fatigue, ME/CFS presents an array of other core symptoms, including autonomic nervous system (ANS) dysfunction, sustained inflammation, altered energy metabolism, and mitochondrial dysfunction. Here, we evaluated patients' symptomatology and the mitochondrial metabolic parameters in peripheral blood mononuclear cells (PBMCs) and plasma from a clinically well-characterised cohort of six ME/CFS patients compared to age- and gender-matched controls. We performed a comprehensive cellular assessment using bioenergetics (extracellular flux analysis) and protein profiles (quantitative mass spectrometry-based proteomics) together with self-reported symptom measures of fatigue, ANS dysfunction, and overall physical and mental well-being. This ME/CFS cohort presented with severe fatigue, which correlated with the severity of ANS dysfunction and overall physical well-being. PBMCs from ME/CFS patients showed significantly lower mitochondrial coupling efficiency. They exhibited proteome alterations, including altered mitochondrial metabolism, centred on pyruvate dehydrogenase and coenzyme A metabolism, leading to a decreased capacity to provide adequate intracellular ATP levels. Overall, these results indicate that PBMCs from ME/CFS patients have a decreased ability to fulfill their cellular energy demands.

scholarly journals Linkage of IgA deficiency to Gm allotypes; the influence of Gm allotypes on IgA-IgG subclass deficiency

2008 ◽  
Vol 99 (2) ◽  
pp. 211-215 ◽  
Author(s):  
V.-A. OXELIUS ◽  
A.-M. CARLSSON ◽  
L. HAMMARSTRÖM ◽  
J. BJÖRKANDER ◽  
L. Å. HANSON
Keyword(s):  
Iga Deficiency ◽  
Igg Subclass ◽  
Igg Subclass Deficiency ◽  
Gm Allotypes ◽  
Subclass Deficiency

IgG Subclass Deficiency

2009 ◽  
pp. 1032-1032
Author(s):  
Stanley M. Gartler ◽  
R. Scott Hansen ◽  
Vinzenz Oji ◽  
Heiko Traupe ◽  
Julia Horn ◽  
...  
Keyword(s):  
Igg Subclass ◽  
Igg Subclass Deficiency ◽  
Subclass Deficiency
Sign in / Sign up

Export Citation Format

Share Document